Clinical trials have formally demonstrated that in chronic myeloid leukemia (CML), patients
treated with tyrosine kinase inhibitors (TKI) who achieved and maintained deep molecular …

Tyrosine kinase inhibitors (TKIs) represent a major breakthrough in the treatment of chronic
myeloid leukemia (CML). Thanks to these agents, CML has been transformed from a …

Abstract Purpose of Review Chronic myeloid leukemia (CML) patients treated with tyrosine
kinase inhibitors (TKI) have near-normal life expectancy. However, lifelong TKI therapy is …

Discontinuation of tyrosine kinase inhibitors (TKIs) is now a feasible therapeutic goal for
patients with chronic phase chronic myeloid leukemia (CML‐CP). Whereas approximately …

The dramatic success of tyrosine kinase inhibitors (TKIs) has led to the widespread
perception that chronic myeloid leukemia (CML) has become another chronic disease …

BACKGROUND The ultimate goal of chronic myeloid leukemia management in the tyrosine
kinase inhibitor (TKI) era for patients who obtain deep molecular responses is maintaining a …

Simple Summary Chronic myeloid leukemia (CML) is a blood cancer. Unlike other cancers
CML treatment is lifelong and many patients experience side effects. For those patients who …

Abstract Purpose of Review Discontinuation of tyrosine kinase inhibitors (TKIs) in chronic
phase chronic myeloid leukemia (CP-CML) patients has become a reality. Treatment-free …

The advent of tyrosine kinase inhibitors (TKI) into the management of patients with chronic
myeloid leukemia (CML) has profoundly improved prognosis. Survival of responders is …

Chronic myeloid leukemia (CML) is the best example of successful targeted therapy. Today,
the overall survival of patients with CML treated by using tyrosine kinase inhibitors (TKIs) is …